SCHEMBL4722516

SCHEMBL4722516

CCCCN(CCCC)N1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
SIGMAR1 Q99720 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723247 0.98 L3MBTL1 (0.36) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL4724012 0.95 SIGMAR1 (0.35) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL8607396 0.95 SIGMAR1 (0.33) L3MBTL1SIGMAR1
SCHEMBL4722021 0.93 L3MBTL1 (0.34) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL10444399 0.93 DNM1 (0.39) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL8894973 0.91 DNM1 (0.42) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL4765150 0.91 L3MBTL1 (0.32) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL28915967 0.91 DNM1 (0.42) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL26160891 0.89 DNM1 (0.41) L3MBTL1SIGMAR1MEN1KMT2ATDP1
SCHEMBL4721344 0.89 L3MBTL1 (0.34) L3MBTL1SIGMAR1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150274700-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2015-10-01 US disclosed
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
WO-2003042198-A1 ISOTHIAZOLE DERIVATIVES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2003-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 L3MBTL1 3954/4885SIGMAR1 1026/4885MEN1 4451/4885
US-20150274700-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 L3MBTL1 4496/4885SIGMAR1 887/4885MEN1 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.